NEW YORK (GenomeWeb News) – Leerink Swann today upgraded Illumina to an Outperform rating, saying the demand for its HiSeq next-generation sequencing platform has normalized, while interest among researchers in sequencing has remained high.

Separately, the investment firm revised estimates for Life Technologies, Thermo Fisher Scientific, Affymetrix, PerkinElmer, Bio-Rad Laboratories, Bruker, and Waters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.